| Movement Disorders |
2005-004685-17: A prospective placebo controlled study of botulilium toxin (BOTOX) on gait disorder induced by spastic equinovarus foot. |
|
|
| Ongoing | 4 | 12 | Europe | BOTOX, Powder and solvent for solution for injection, BOTOX | CUB - Hôpital Erasme | Spastic equinus foot is a common dynamic deformity in patients with cerebral palsy. This dynamic deformity, mainly caused by spasticity of the soleus, gastrocnemius and tibialis posterior muscles, may lead to gait impairment. | | | | |
2010-018345-64: Evaluation of the efficacy of Xeomin in the treatment of cervical dystonia (CD) and blepharospasmus (BS) in patients who did not respond to treatment with Botox. |
|
|
| Ongoing | 4 | 30 | Europe | Powder for solution for injection, XEOMIN, BOTOX | POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | cervical dystonia, blepharospasmus (BS) | | | | |
| Ongoing | 4 | 100 | Europe | Baclofen, Tablet, Baclofen - generic product | Central and North West London NHS Foundation Trust | GHB/GBL Withdrawal Syndrome, Using GHB/GBL repeatedly can cause severe withdrawal symptoms, including insomnia, anxiety, tremors, and increased heart rate and blood pressure, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2014-005422-35: The role of Buspirone in attenuating involuntary movements (Dyskinesias) in patients with Parkinson's disease. |
|
|
| Ongoing | 4 | 24 | Europe | Buspirone Hydrochloride, Tablet, Buspirone Hydrochloride | Imperial College London-Imperial College Healthcare NHS Trust, The Michael J Fox Foundation for Parkinson's Research | Levodopa induced dyskinesias within Parkinson's disease., Parkinson's disease, Diseases [C] - Nervous System Diseases [C10] | | | | |
2005-000431-22: VALUTATION OF PLACEBO EFFECT AFTER CONDITIONING WITH APOMORPHINE AND WITHOUT PHARMACOLOGICAL CONDITIONING ON THE RIGIDITY AND ELECTRICAL ACTIVITY OF NEURONS OF SUBTHALAMIC NUCLEUS IN PARKINSON PATIENTS. |
|
|
| Ongoing | 4 | | Europe | APOFIN STYLO*1 PENNA 3ML 1%, APOFIN STYLO*1 PENNA 3ML 1% | AZIENDA SANITARIA OSPEDALIERA \"S. GIOVANNI BATTISTA DI TORINO\" | THE TOPICAL INVESTIGATION IS THE BASE OF PATOLOGY | | | | |
2004-002608-13: Pragmatic Randomised Control Trial of Quetiapine for psychosis in Parkinson’s Disease |
|
|
| Ongoing | 4 | 60 | Europe | Seroquel, Seroquel, Seroquel | King’s College London & King’s College Hospital | Parkinson\'s Disease with psychosis | | | | |
2004-005034-39: Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson\'s disease |
|
|
| Ongoing | 4 | 60 | Europe | NICOTINAMIDE, Nicotinamide, Nicotinamide | Queen Elizabeth Hospital | Idiopathic Parkinson\'s disease | | | | |
2005-001516-41: Efficacy and safety of Levetiracetam treatment in patients suffering from Restless Legs SyndromeEficacia y seguridad de un tratamiento con levetiracetam en pacientes con síndrome idiopático de piernas inquietas |
|
|
| Ongoing | 4 | 12 | Europe | Levetiracetam, Keppra 250, Keppra 500, Keppra 250, Keppra 500 | Clínica Plató Fundació Privada | Restless legs syndrome (RLS) | | | | |
2005-002042-19: Double-blind, placebo controlled cross-over study to assess the efficacy of Levetiracetam in paediatric and childhood non-epileptic myoclonusEstudio cruzado, aleatorizado, doble ciego controlado con placebo, para evaluar la eficacia del Levetiracetam en el tratamiento del mioclonus no epiléctico en pacientes pediátricos y adolescentes |
|
|
| Ongoing | 4 | 20 | Europe | Levetiracetam, Keppra 250 mg, Keppra 500 mg, Keppra 250 mg, Keppra 500 mg | Hospital Sant Joan de Déu | Non-epileptic myoclonus | | | | |
2005-002041-40: Double-blind, placebo controlled cross-over study to assess efficacy of Levetiracetam in paediatric and childhood Tourette syndrome. Estudio cruzado, aleatorizado, doble ciego controlado con placebo, para evaluar la eficacia del Levetiracetam en el control de los tics de pacientes pediátricos y adolescentes con síndrome de Gilles de la Tourette |
|
|
| Ongoing | 4 | 20 | Europe | Levetiracetam, Keppra 250 mg, Keppra 500 mg, Keppra 250 mg, Keppra 500 mg | Hospital Sant Joan de Déu | Tourette syndrome | | | | |
2005-004122-70: Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine. |
|
|
| Ongoing | 4 | 30 | Europe | Prevenar, Prevenar | Great Ormond Street Hospital | Ataxia Telangiectasia (AT) is a genetic condition in which there is a deficiency of the immune system with excessive susceptibility to pneumonia and other infections. | | | | |
2005-003903-35: : The Role of Keppra in the Treatment of Tremor in Multiple Sclerosis |
|
|
| Ongoing | 4 | 20 | Europe | Keppra ®, Keppra 250mg, Keppra 500mg | Newcastle-upon-Tyne Hospitals NHS Trust | Multiple Sclerosis | | | | |
2006-005140-89: A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS |
|
|
| Ongoing | 4 | 160 | Europe | Rasagiline 1mg tablet, Rasagiline 2 mg tablet, TVP-1012, Selegiline HCl 5 PCH, Nardil, Selegiline HCl 5 PCH, Nardil | TEVA Pharmaceuticals Industries Ltd | This postmarketing Phase I study is performed in healthy volunteers. The IMP rasagiline 1mg is indicated for the treatment of Parkinson\'s Disease (PD). | | | | |
2006-002408-32: Modulación dopaminérgica de las funciones cognitivas y afectivas por el tratamiento con diferentes métodos de estimulación dopaminérgica en la enfermedad de Parkinson . Implicaciones para el tratamiento con levodopa. |
|
|
| Ongoing | 4 | 20 | Europe | Levodopa-carbidopa-entacapone, Levodopa/Carbidopa, Stalevo 150, Sinemet, Stalevo 150, Sinemet | Institut de Recerca del Hospital de la Santa Creu i Sant Pau | Fluctuaciones motoras, cognitivas y del humor en la enfermedad de Parkinson. | | | | |
2006-006684-22: Evaluation des effets à long terme de l’amantadine chez le parkinsonien souffrant de dyskinésies induites par la lévodopa : Etude randomisée en double-insu versus placebo de l’arrêt d’une prescription chronique. |
|
|
| Ongoing | 4 | 80 | Europe | MANTADIX, MANTADIX | CHU Toulouse | maladie de parkinson | | | | |
2006-005567-26: Effects of deep brain stimulation of the nucleus accumbens on the dopaminergic activity in patients with Gilles-de-la-Tourette-syndrome |
|
|
| Ongoing | 4 | 6 | Europe | [18F] Fallypride, Propofol, | University of Aachen | The participants under study are recruited from a sample of patients suffering from a severe form of the Gilles-de-la-Tourette-syndrome who are waiting to receive deep-brain stimulation of the ncl. accumbens as therapeutic treatment. | | | | |
2007-004001-96: Efectos del tratamiento con deferiprone sobre la hipertrofia miocárdica y los parámetros de función cardiaca en pacientes afectos de Ataxia de Friedreich |
|
|
| Ongoing | 4 | 16 | Europe | Ferriprox, Ferriprox | Hospital Sant Joan de Déu | La Ataxia de Friedreich es una enfermedad causada por un déficit de la proteína frataxina. Su déficit produce acúmulo de hierro libre intramitocondrial, un incremento de la producción de radicales libres y al daño celular por estrés oxidativo. Evaluaremos la evolución cardiaca y neurológica con los datos del seguimiento de los cinco años pasados en tratamiento exclusivo con idebenona y a partir del nuevo tratamiento con deferiprone asociado a idebenona. | | | | |
2007-003017-14: A comparison of the effect of Atropine and Botulinum-toxin in patients with severe drooling |
|
|
| Ongoing | 4 | 40 | Europe | Botox, Atropin Chauvin, M03AX01, S01FA01, Botox, Atropin Chauvin, Botox, Atropin Chauvin | Käkkliniken, Universitetssjukhuset i Linköping | Patients with ALS, Parkinson´s disease, brain-damage cerebral paralysis or other neurological conditions often have an impaired swallowing, resulting in drooling. This adds a social handicap and often also causes facial dermatitis, especially around the mouth. | | | | |
2008-003581-26: Pharmacokinetics of levodopa using duodenal levodopa/carbidopa infusion with and without oral COMT inhibitors |
|
|
| Ongoing | 4 | 10 | Europe | Duodopa, Comtess, Tasmar, Duodopa, Comtess, Tasmar | Dept of Neuroscience, Uppsala University | Parkinson\'s disease (G20.9), advanced, patients presently on Duodopa treatment. | | | | |
2007-007397-28: Evaluation de la tolérance et de l’acceptabilité de la Rasagiline dans le traitement de la maladie de Parkinson au stade précoce |
|
|
| Ongoing | 4 | 240 | Europe | Azilect, Sifrol, Azilect, Sifrol, Azilect, Sifrol | Qualissima | Maladie de Parkinson idiopathique au stade précoceMaladie de Parkinson, numéro de classification MedDRA 10061536 | | | | |
2008-006278-13: Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations. |
|
|
| Ongoing | 4 | 10 | Europe | Reminyl Retard, Sinemet 125 mg, Reminyl Retard, Sinemet 125 mg | UMCG | patients with advanced (>5 years) Parkinson\'s disease and visual hallucinations. | | | | |
2008-007626-19: Traitement par la toxine botulinique de la dystonie en griffe des orteils chez les patients parkinsoniens : Comparaison de l’efficacité d’injections effectuées dans la musculature extrinsèque (le long fléchisseur des orteils) et dans la musculature intrinsèque (la chair carrée/le court fléchisseur plantaire). |
|
|
| Ongoing | 4 | 45 | Europe | XEOMIN, XEOMIN | CHU Clermont-Ferrand | Patients parkinsoniens présentant une dystonie en griffe des orteils | | | | |
2009-012529-12: A randomised, REQUIP® IR-controlled, n-of-1, multiple crossover, pilot trial of the effect of REQUIP®CR on abnormal daytime somnolence in patients with Parkinson’s Disease |
|
|
| Ongoing | 4 | 10 | Europe | ropinirole, REQUIP-LP, REQUIP, REQUIP-LP, REQUIP | CHU de Toulouse | parkinson\'s disease | | | | |
2008-005819-18: A comparison of Dysport (100 U/ml) and Botox (100 U/ml) using dose conversion factor 3:1 and 1.7:1 in the treatment of cervical dystonia. |
|
|
| Ongoing | 4 | 75 | Europe | Botox, Dysport, Botox, Dysport, Botox, Dysport | Department of Neuroscience, Uppsala University | Cervical dystonia, not multifocal or generalised dystonia. | | | | |
2009-013473-18: Reconnaissance des émotions et neurones miroirs dans la maladie de Parkinson |
|
|
| Ongoing | 4 | 40 | Europe | MODOPAR, MODOPAR, MODOPAR | CHU Clermont-Ferrand | maladie de Parkinson | | | | |
2009-012643-42: Freezing of gait in Parkinson\'s disease: in search of the underlying mechanism and the application of a new treatment option |
|
|
| Ongoing | 4 | 40 | Europe | Not applicable, Not applicable, Ritalin, Ritalin | University Medical Center Groningen | Parkinson\'s disease, in particular the symptom Freezing of Gait | | | | |
2010-019737-94: ESTUDIO ABIERTO, DE EFICACIA, TOLERANCIA Y SEGURIDAD DEL TRATAMIENTO CON EL FACTOR TRÓFICO IGF-I EN LA ATAXIA CEREBELOSA DEGENERATIVA |
|
|
| Ongoing | 4 | 20 | Europe | -, INCRELEX 10 mg/ml solución inyectable., INCRELEX 10 mg/ml solución inyectable. | FIBHULP | Ataxia cerebelosa degenerativa de grado leve a moderado | | | | |
2010-019198-14: Icke-motoriska och hälsoekonomiska effekter av intermittent subkutan apomorfinbehandling vid Parkinsons sjukdom |
|
|
| Ongoing | 4 | 30 | Europe | Apo-GO Pen, Apo-GO Pen, Apo-GO Pen | Karolinska Universitetssjukhuset Huddinge | Parkinsons sjukdom | | | | |
2010-022363-35: Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson\'s Disease: A randomised, placebo-controlled double-blind trial. |
|
|
| Ongoing | 4 | 24 | Europe | Levodopa / Benserazid, Rotigotin, LD / BE, RO, Madopar LT, Neupro, Madopar LT, Neupro | Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University | Parkinson\'s disease | | | | |
2012-001218-40: EFFICACY OF ROTIGOTINE ON GAIT PERFORMANCE OF PARKINSONIAN PATIENTS Efficacia della rotigotina sul cammino nei pazienti con malattia di Parkinson |
|
|
| Ongoing | 4 | 25 | Europe | NEUPRO*7CER 4MG/24H, NEUPRO*7CER 6MG/24H, NEUPRO*7CER 8MG/24H, NEUPRO*28CER 2MG/24H, NEUPRO*28CER 4MG/24H, NEUPRO*28CER 6MG/24H, NEUPRO*28CER 8MG/24H, NEUPRO*7CER 4MG/24H, NEUPRO*7CER 6MG/24H, NEUPRO*7CER 8MG/24H, NEUPRO*28CER 2MG/24H, NEUPRO*28CER 4MG/24H, NEUPRO*28CER 6MG/24H, NEUPRO*28CER 8MG/24H | FONDAZIONE SANTA LUCIA, UCB PHARMA SPA | Patients suffering for Idiopathic Parkinson’s Disease. H&Y stage > or = 2 with un-satisfactory control by on-going pharmacological therapy (Levodopa, COMT & MAO-inhibitors), characterised by an incomplete control of motor signs, in particular presence of early morning akinesia, as well as gait deficits in the morning. Pazienti affetti da Malattia di Parkinson idiopatica di media gravità (H&Y stage > or = 2) con un non soddisfacente controllo della terapia farmacologica (Levodopa, COMT & MAO-inhibitors) caratterizzato da un incompleto controllo dei sintomi con particolare riferimento ad una acinesia del mattino che determini una alterazione del cammino | | | | |
2012-000801-64: A study of the effects of medication on memory in Parkinson\'s Disease |
|
|
| Ongoing | 4 | 55 | Europe | Pramipexole dihydrochloride monohydrate extended release, Ropinirole hydrochloride prolonged release, N/A, Mirapexin extended release various strengths, Requip prolonged release, Mirapexin extended release various strengths, Requip prolonged release | University Hospital of North Staffordshire, Keele University, National Institute for Health Research | Idiopathic Parkinson\'s Disease | | | | |
2013-004229-10: Placebo effect in Parkinson\'s disease El efecto placebo en la enfermedad de Parkinson |
|
|
| Ongoing | 4 | 60 | Europe | Sinemet 25/250, Sinemet 25/250 | Raul de la Fuente-Fernandez, Complejo Hospitalario Universitario de Ferrol (CHUF) | Parkinson\'s disease Enfermedad de Parkinson | | | | |
| Ongoing | 4 | 20 | Europe | Victoza, Byetta, Victoza, Byetta, Victoza, Byetta | CUB - Hôpital Erasme, Friedreich's Ataxia Research Alliance | Friedreich\'s Ataxia | | | | |
2014-001014-25: Brain amyloid beta burden as per florbetaben PET Medición de carga amiloidosis cerebral con técnica PET y florbetaben |
|
|
| Ongoing | 4 | 40 | Europe | Neuraceq, Solution for injection, Neuraceq | Fundació ClÃnic per la Recerca Biomèdica, Fundació ClÃnic per a la Recerca Biomèdica | Parkinson's Disease Enfermedad de Parkinson, Parkinson's Disease Enfermedad de Parkinson, Diseases [C] - Nervous System Diseases [C10] | | | | |
2016-001690-33: Apomorfiini-infuusiohoito edenneen Parkinsonin taudin hoidossa Apomorfiini-infuusiohoito edenneen Parkinsonin taudin hoidossa |
|
|
| Ongoing | 4 | 5 | Europe | Dacepton 5 mg/ml, Infusion, Dacepton 5 mg/ml infuusioneste, liuos | Eero Pekkonen, NordicInfu Care | Edennyt parkinsonin tauti Edennyt parkinsonin tauti, Edennyt parkinsonin tauti Edennyt parkinsonin tauti, Diseases [C] - Nervous System Diseases [C10] | | | | |
2017-000784-33: Study on the effect of switching to Envarsus in renal transplant patients with tacrolimus-associated tremor Estudio clínico en pacientes trasplantados de riñón para estudiar el efecto del cambio a Envarsus en el temblor asociado a tacrolimus. |
|
|
| Ongoing | 4 | 20 | Europe | tacrolimus, EU/1/14/935/004, Tablet, Envarsus prolonged-release tablets | Fundació Clínic per a la Recerca Biomèdica, Chiesi | Tacrolimus-associated tremor Temblor asociado al tratamiento con tacrolimus, Tacrolimus-associated tremor Temblor asociado al tratamiento con tacrolimus, Diseases [C] - Nervous System Diseases [C10] | | | | |
2017-003254-17: Safety and efficacy of Safinamide (Xadago®) in apathy associated with Parkinson's disease Seguridad y eficacia de la Safinamida (Xadago®) en la apatÃa asociada a la enfermedad de Parkinson |
|
|
| Ongoing | 4 | 36 | Europe | Film-coated tablet, Xadago | Institut de Recerca Hospital de la Santa Creu i Sant Pau, Institut de Recerca Hospital de la Santa Creu i Sant Pau | Parkinson's disease Enfermedad de Parkinson, Parkinson's disease Enfermedad de Parkinson, Diseases [C] - Nervous System Diseases [C10] | | | | |
